RTGN RetinalGenix Technologies Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1836295 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY24.0%
TTM EPS YoY26.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-10,293.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets8,297.1%
Debt / equity—
Current ratio0.01x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.23x
Accruals ratio-7,939.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $83,040 | $373,271 | $524,183 | $809,255 | $747,808 |
| SG&A expense | $1.30M | $1.33M | $898,658 | $807,406 | $1.12M |
| Interest expense | $4,005 | $3,840 | $3,840 | $5,140 | $2,619 |
| Net income | -$2.43M | -$4.32M | -$2.09M | -$3.91M | -$2.18M |
| EPS (basic) | -0.13 | -0.24 | -0.12 | -0.25 | -0.05 |
| EPS (diluted) | -0.13 | -0.24 | -0.12 | -0.25 | -0.05 |
| Weighted avg. shares (diluted) | 18.56M | 17.94M | 17.35M | 15.58M | 41.25M |
| Balance sheet | |||||
| Cash & equivalents | $14,774 | $6,060 | $0 | $38 | $4,947 |
| Current assets | $14,774 | $6,060 | $0 | $38 | $4,947 |
| PP&E, net | — | $56 | $156 | $256 | — |
| Total assets | $21,041 | $14,946 | $156 | $294 | $4,947 |
| Current liabilities | $2.32M | $1.47M | $1.41M | — | — |
| Total liabilities | $2.32M | $1.48M | $1.41M | $1.07M | $469,622 |
| Shareholders' equity | -$2.30M | -$1.46M | -$1.41M | -$1.07M | -$464,675 |
| Shares outstanding | 18.84M | 18.52M | 17.64M | 17.27M | 14.22M |
| Cash flow statement | |||||
| Operating cash flow | -$558,350 | -$741,936 | -$451,661 | -$199,287 | -$1.17M |
| Financing cash flow | $567,064 | $747,996 | $451,623 | $194,685 | $1.17M |
| Depreciation & amortization | $56 | $100 | $100 | $51 | — |
| Stock-based compensation | $1.04M | $2.61M | $664,208 | $259,300 | $307,918 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.